Skip to Main Content
American Society of Hematology Logo Open Menu
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2018, Issue 1
November 30 2018
Hematology Cover Image for Volume 2018, Issue 1
In this Issue

Table of Contents

Ham-Wasserman Lecture

On the architecture of translational research designed to control chronic lymphocytic leukemia
Michael Hallek
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

A Panoply of Immunotherapies for Adult B-Lineage Acute Lymphoblastic Leukemia

Antibody-based therapies in patients with acute lymphoblastic leukemia
Shira Dinner,Michaela Liedtke
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Are CAR T cells better than antibody or HCT therapy in B-ALL?
Michael A. Pulsipher
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
Tania Jain,Mark R. Litzow
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Acute Myeloid Leukemia: Moving Beyond 7+3

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Gregory W. Roloff,Elizabeth A. Griffiths
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
New drugs for acute myeloid leukemia inspired by genomics and when to use them
Daniel A. Pollyea
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Cytotoxic therapy in acute myeloid leukemia: not quite dead yet
Laura C. Michaelis
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Aggressive Lymphomas

Challenges and implications of genomics for T-cell lymphomas
Eric D. Jacobsen,David M. Weinstock
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Genomics of aggressive B-cell lymphoma
Allison Rosenthal,Lisa Rimsza
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Novel therapies for relapsed/refractory aggressive lymphomas
Jonathon B. Cohen
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Approach to the Treatment of the Older, Unfit Patient with Myeloma from Diagnosis to Relapse

Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist
Thierry Facon,Kenneth Anderson
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist
Tanya M. Wildes,Kenneth C. Anderson
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Approach to the Treatment of the Young, Fit Patient with Myeloma from Diagnosis to Relapse

Treatment approach for young, fit, newly diagnosed multiple myeloma patients
Saad Z. Usmani,Eric Seifter
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients
Sergio Giralt,Eric Seifter
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

As if Myeloproliferative Neoplasms Weren't Already Challenging Enough

JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy
Michele Ciboddo,Ann Mullally
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF
Robyn M. Scherber,Ruben A. Mesa
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
The new tool “KIT” in advanced systemic mastocytosis
William Shomali,Jason Gotlib
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

AYA: Big Children or Small Adults? Leukemia Treatment in Adolescence

Genetics and prognosis of ALL in children vs adults
Kathryn G. Roberts
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Long-term complications in adolescent and young adult leukemia survivors
K. Scott Baker,Karen L. Syrjala
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Adolescent angst: enrollment on clinical trials
Theresa H. M. Keegan,Helen M. Parsons
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Chronic Myeloid Leukemia: With Great Success Comes Great Responsibility

The argument for using imatinib in CML
Simone Claudiani,Jane F. Apperley
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
Naranie Shanmuganathan,Timothy P. Hughes
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
We do still transplant CML, don’t we?
Charles F. Craddock
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Follicular Lymphoma: Have We Made Progress?

Where to start? Upfront therapy for follicular lymphoma in 2018
John P. Leonard,Loretta J. Nastoupil,Christopher R. Flowers
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Sequencing of therapies in relapsed follicular lymphoma
Loretta J. Nastoupil,Christopher R. Flowers,John P. Leonard
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Novel immunotherapy approaches to follicular lymphoma
Christopher R. Flowers,John P. Leonard,Loretta J. Nastoupil
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hodgkin Lymphoma: Beyond ABVD for Everyone

Risk-adapted therapy for advanced-stage Hodgkin lymphoma
Michael A. Spinner,Ranjana H. Advani
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy
Alison J. Moskowitz
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Where does PD-1 blockade fit in HL therapy?
Alex F. Herrera
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Reining in Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

GVHD: biology matters
James L. M. Ferrara,Mohammed S. Chaudhry
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation
Betty Ky Hamilton
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Biology-driven developments in the therapy of acute graft-versus-host disease
Robert Zeiser
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The Future of CLL Therapy

Selecting Frontline Therapy for CLL in 2018
Nitin Jain
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Relapsed CLL: sequencing, combinations, and novel agents
Jennifer R. Brown
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Richter transformation in the era of novel agents
Wei Ding
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The Molecular Maelstrom of Myelodysplastic Syndromes

Clinical consequences of clonal hematopoiesis of indeterminate potential
David P. Steensma
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
The MDS genomics-prognosis symbiosis
Aziz Nazha
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Treatments targeting MDS genetics: a fool’s errand?
Amy E. DeZern
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Using Genomics to Risk Stratify and Treat Kids

Using genomics to define pediatric blood cancers and inform practice
Rachel E. Rau,Mignon L. Loh
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Ethical conundrums in pediatric genomics
Seth J. Rotz,Eric Kodish
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
JMML genomics and decisions
Charlotte M. Niemeyer
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Anxiety-Provoking Consults: Macrophage Activation Syndrome, Castleman Disease, and Hypereosinophilia

The rheumatology/hematology interface: CAPS and MAS diagnosis and management
John M. Gansner,Nancy Berliner
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease
David C. Fajgenbaum
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Hypereosinophilic syndrome: approach to treatment in the era of precision medicine
Amy Klion
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Delivering High-Quality Oral Anticoagulant Therapy: State of the Art in 2018

Optimizing quality care for the oral vitamin K antagonists (VKAs)
Vittorio Pengo,Gentian Denas
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions
Sara R. Vazquez
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Role of the anticoagulant monitoring service in 2018: beyond warfarin
Nathan P. Clark
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Thalassemia Syndromes: Diagnosis and Management in a Changing World

Potential new approaches to the management of the Hb Bart’s hydrops fetalis syndrome: the most severe form of α-thalassemia
Andrew J. King,Douglas R. Higgs
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy
John Porter
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hemolytic Anemia: A Cornucopia of Causes

Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria
Samuel A. Merrill,Robert A. Brodsky
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Inherited hemolytic anemia: a possessive beginner’s guide
Narla Mohandas
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Autoimmune hemolytic anemia
Anita Hill,Quentin A. Hill
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hemostatic and Thromboembolic Challenges in the Young

Evaluation and management of heavy menstrual bleeding in adolescents: the role of the hematologist
Sarah H. O’Brien
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Management of thrombosis in children and neonates: practical use of anticoagulants in children
Paul Monagle,Fiona Newall
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Pediatric ITP: is it different from adult ITP?
Jenny M. Despotovic,Amanda B. Grimes
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

High-Performance Hematology: Elite Athletes and Weekend Warriors

Elite athletes and anticoagulant therapy: an intermittent dosing strategy
Stephan Moll,Joshua N. Berkowitz,Christopher W. Miars
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Balancing exercise risk and benefits: lessons learned from sickle cell trait and sickle cell anemia
Robert I. Liem
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Long-Term Management of VTE: The First 6 Months and Beyond

Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Marc Alan Rodger,Gregoire Le Gal
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Breadth of complications of long-term oral anticoagulant care
Walter Ageno,Marco Donadini
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Anticoagulating patients with high-risk acquired thrombophilias
Leslie Skeith
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Severe Aplastic Anemia: Diagnosis and Management in an Era of Effective Therapies

Activity of eltrombopag in severe aplastic anemia
Phillip Scheinberg
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
A brief, but comprehensive, guide to clonal evolution in aplastic anemia
Daria V. Babushok
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Alternative donor transplants for severe aplastic anemia
Andrea Bacigalupo
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Sickle Cell Disease: New Frontiers

The current state of sickle cell trait: implications for reproductive and genetic counseling
Lydia H. Pecker,Rakhi P. Naik
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Measuring success: utility of biomarkers in sickle cell disease clinical trials and care
Ram Kalpatthi,Enrico M. Novelli
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
New insights into the pathophysiology and development of novel therapies for sickle cell disease
Scott Moerdler,Deepa Manwani
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The Interface Between “Man and Machine”: Managing Hemostasis and Thrombosis in the Plastic and Metal Circulation

Adult and pediatric mechanical circulation: a guide for the hematologist
Lisa Baumann Kreuziger,M. Patricia Massicotte
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
An introduction to point-of-care testing in extracorporeal circulation and LVADs
Rachel Sara Bercovitz
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Preventing and managing catastrophic bleeding during extracorporeal circulation
Keyvan Karkouti,Loretta T. S. Ho
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

TTP 2019: State of the Art

Clinical and laboratory diagnosis of TTP: an integrated approach
Thita Chiasakul,Adam Cuker
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura
Kathryn Dane,Shruti Chaturvedi
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
TTP: long-term outcomes following recovery
James N. George
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Update in Transfusion Therapy for Hematological Malignancies: Transfusion Support—TACO and TRALI

Shifting ground and gaps in transfusion support of patients with hematological malignancies
Christine Cserti-Gazdewich
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
TACO and TRALI: biology, risk factors, and prevention strategies
Nareg Roubinian
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

What's Hot in ITP

How do we diagnose immune thrombocytopenia in 2018?
John G. Kelton,John R. Vrbensky,Donald M. Arnold
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Evidence-based management of immune thrombocytopenia: ASH guideline update
Cindy E. Neunert,Nichola Cooper
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Drug-associated thrombocytopenia
Tamam Bakchoul,Irene Marini
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Erratum

Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Hematology Am Soc Hematol Educ Program. 2017;2017:400-405.
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
  • Cover Image

    Cover Image

    issue cover

    Composite colored scanning electron micrograph of a bacterial blood infection caused by a rod-shaped bacterium. Short chains of a bacillus bacterium are shown among red blood cells and platelets from the circulatory system. Magnification: × 1600 when the shortest axis is printed at 25 mm. Source: Dennis Kunkel Microscopy/Science Photo Library.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkEditorial Board
All Issues
Targeted medical therapies for vascular anomalies
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma
Transplant in ALL: who, when, and how?
Ph− ALL: immunotherapy in upfront treatment
Ph+ ALL: new approaches for upfront therapy
  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal